ArticleCell biology and toxicology2023
AS3MT facilitates NLRP3 inflammasome activation by m
Article in Cell biology and toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Endocrine disruptors are contributing to type 2 diabetes mellitus.Hormones (Athens, Greece) · 2026Review
- METTL16 promotes MASLD progression through the regulation of lipid synthesis and immune response.Biology direct · 2026Article
- m6A RNA modification and its emerging roles in diseases: recent advances and therapeutic implications.Journal of translational medicine · 2026Review
- METTL14-dependent regulation of HMGB1 attenuates inflammation in diabetic retinopathy.Acta diabetologica · 2026Article
- Mitochondria at the intersections of RNA modifications and metabolism reprogramming implications in cell death, tumor microenvironment, and immunotherapy.Journal of hematology & oncology · 2025Review
- Novel role of FTO in regulation of gut-brain communication viaGut microbes · 2025Article
- Updated insights into the molecular networks for NLRP3 inflammasome activation.Cellular & molecular immunology · 2025Review
- Unveiling the dynamics and therapeutic potential of mInternational journal of biological sciences · 2025Review
- Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks.Frontiers in immunology · 2025Review
- Alternative polyadenylation regulates the translation of metabolic and inflammation-related proteins in adipose tissue of gestational diabetes mellitus.Computational and structural biotechnology journal · 2024Article
- Emerging roles of NHeliyon · 2024Review
- RNA modifications in the progression of liver diseases: from fatty liver to cancer.Science China. Life sciences · 2024Review
- Article
- Association between Heavy Metals, Metalloids and Metabolic Syndrome: New Insights and Approaches.Toxics · 2023Review
- mActa biochimica et biophysica Sinica · 2023Review
- Critical Overview on Endocrine Disruptors in Diabetes Mellitus.International journal of molecular sciences · 2023Review
- N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism.Frontiers in endocrinology · 2023Review
- Role of NLRP3 inflammasome and oxidative stress in hepatic insulin resistance and the ameliorative effect of phytochemical intervention.Frontiers in pharmacology · 2023Review
- The Epitranscriptomic Mechanism of Metal Toxicity and Carcinogenesis.International journal of molecular sciences · 2022Review
- Pyroptosis and Insulin Resistance in Metabolic Organs.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.